117.22BMarket Cap24.25P/E (TTM)
47.220High46.810Low2.63MVolume46.900Open47.220Pre Close123.46MTurnover0.12%Turnover Ratio20.36P/E (Static)2.50BShares53.45452wk High1.48P/B103.09BFloat Cap40.89752wk Low1.91Dividend TTM2.20BShs Float53.461Historical High4.08%Div YieldTTM0.87%Amplitude8.844Historical Low46.985Avg Price1Lot Size
Sanofi Stock Forum
NVAX closed Monday at $16, down 11.9% for the day and 32.9% from the $23.86 19-month intraday high that it hit last Thursday.
Prior to the recent sell-off, Novavax had gained 438.6% between its $4.43 intraday low on May 9 and its $23.86 intraday peak on...
Alright, folks, let’s dive into the world of biotech drama. Shares of Novavax (NVAX) have been on a tear, continuing their climb on Monday after the company dropped some major news last week. They announced a licensing deal with Sanofi, and the stock shot up 47.6%, closing at $13.11. That's the highest it's been since December 2022.
But wait, there's more! Novavax shares had already doubled last Friday on this news, and over the past three months, t...
MACRO
This week, investors can expect macroeconomic data prints in the form of PPI on Tuesday, and CPI prints Wednesd...
👉 Key Highlights:
📍 Novavax's shares jump 120% in premarket trading after announcing a deal with Sanofi.
📍 Partnership to co-commercialize Covid vaccine and develop combination flu shots.
📍 Sanofi to make an upfront payment of $500 million to Novavax, with potential for up to $700 million more.
📍 Deal includes royalties and up to $200 million in additional milestones.
📍 Sanofi acquires less than ...
$AbbVie(ABBV.US)$ +189%
$Bristol-Myers Squibb(BMY.US)$ +175%
$Johnson & Johnson(JNJ.US)$ +95%
$AstraZeneca(AZN.US)$ +78%
$NVM +45%
$Merck & Co(MRK.US)$ +37%
$ROCHE HOLDING AG(RHHBY.US)$ +27%
$Pfizer(PFE.US)$ +13%
$GlaxoSmithKline(GSK.US)$ +13%
----- $SPDR S&P 500 ETF(SPY.US)$ +12% -----
$Sanofi(SNY.US)$ +3%
Source: Arjun Murthy on the HR app!
$Heron Therapeutics(HRTX.US)$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US)$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US)$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US)$ & $Regeneron Pharmaceuticals(REGN.US)$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
No comment yet